» Articles » PMID: 33290688

Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction

Abstract

Catheter ablation improves clinical outcomes in atrial fibrillation (AF) patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, the role of catheter ablation in HF with a preserved ejection fraction (HFpEF) is less clear. We performed a literature search and systematic review of studies that compared AF recurrence at one year after catheter ablation of AF in patients with HFpEF versus those with HFrEF. Risk ratio (RR; where a RR <1.0 favors the HFpEF group) and mean difference (MD; where MD <0 favors the HFpEF group) 95% confidence intervals (CI) were measured for dichotomous and continuous variables, respectively. Six studies with a total of 1,505 patients were included, of which 764 (51%) had HFpEF and 741 (49%) had HFrEF. Patients with HFpEF experienced similar recurrence of AF 1 year after ablation on or off antiarrhythmic drugs compared with those with HFrEF (RR 1.01; 95% CI 0.76, 1.35). Fluoroscopy time was significantly shorter in the HFpEF group (MD -5.42; 95% CI -8.51, -2.34), but there was no significant difference in procedure time (MD 1.74; 95% CI -11.89, 15.37) or periprocedural adverse events between groups (RR 0.84; 95% CI 0.54,1.32). There was no significant difference in hospitalizations between groups (MD 1.18; 95% CI 0.90, 1.55), but HFpEF patients experienced significantly less mortality (MD 0.41; 95% CI 0.18, 0.94). In conclusion, based on the results of this meta-analysis, catheter ablation of AF in patients with HFpEF appears as safe and efficacious in maintaining sinus rhythm as in those with HFrEF.

Citing Articles

Atrial Fibrillation Recurrence Post-Ablation Across Heart Failure Categories: A Systematic Review and Meta-analysis.

Hashem C, Joseph J, Kinlay S, Peralta A, Hoffmeister P, Yuyun M Cardiol Res. 2025; 16(1):33-43.

PMID: 39897444 PMC: 11779678. DOI: 10.14740/cr2020.


Comparison of Catheter Ablation in Patients with Paroxysmal Non-valvular Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction.

Zhang Z, Lin Q, Wang C, Wu K, Huang Y, Tu T Int J Med Sci. 2025; 22(2):371-382.

PMID: 39781528 PMC: 11704700. DOI: 10.7150/ijms.103170.


2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Arrhythm. 2024; 40(6):1217-1354.

PMID: 39669937 PMC: 11632303. DOI: 10.1002/joa3.13082.


Assessment of Redundant Meta-Analyses on Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure.

Shang L, Shao M, Zhu M, Li J, Gao M, Hou Y Rev Cardiovasc Med. 2024; 25(11):418.

PMID: 39618855 PMC: 11607499. DOI: 10.31083/j.rcm2511418.


Efficacy and safety of catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Chen X, Zhang X, Fang X, Feng S Front Cardiovasc Med. 2024; 11:1423147.

PMID: 39119189 PMC: 11306038. DOI: 10.3389/fcvm.2024.1423147.


References
1.
Mountantonakis S, Grau-Sepulveda M, Bhatt D, Hernandez A, Peterson E, Fonarow G . Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail. 2012; 5(2):191-201. DOI: 10.1161/CIRCHEARTFAILURE.111.965681. View

2.
Olsson L, Swedberg K, Ducharme A, Granger C, Michelson E, McMurray J . Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006; 47(10):1997-2004. DOI: 10.1016/j.jacc.2006.01.060. View

3.
Piccini J, Hammill B, Sinner M, Jensen P, Hernandez A, Heckbert S . Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012; 5(1):85-93. PMC: 3332107. DOI: 10.1161/CIRCOUTCOMES.111.962688. View

4.
Calkins H, Reynolds M, Spector P, Sondhi M, Xu Y, Martin A . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2(4):349-61. DOI: 10.1161/CIRCEP.108.824789. View

5.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. DOI: 10.7326/0003-4819-151-4-200908180-00136. View